Spanish healthcare company Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a manufacturer of plasma-derived medicines, announced on Tuesday that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to develop a treatment for sulfur mustard-induced eye injury.
The treatment uses ocular surface immunoglobulin (OSIG) eye drops to neutralize symptoms caused by the chemical warfare agent.
If successful, the preclinical study could lead to US Food and Drug Administration (FDA) approval for the first medical treatment for sulfur mustard ocular injury.
Grifols is also developing an OSIG treatment for dry eye disease, which is expected to enter clinical trials in 2025.
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
TME Pharma secures EUR2.4m grant for NOX-A12 Phase 2 trial
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Johnson & Johnson reports strong Phase 3 results for TREMFYA in Crohn's Disease
Kind Pharmaceutical's AND017 receives US FDA Orphan Drug Designation
RiboX Therapeutics' RXRG001 Phase I/IIa Study IND application receives US FDA approval
Modalis Therapeutics receives Orphan Drug Designation for MDL-101
EpiVax and CUBRC receive USD2m contract from US FDA
U.P. Oncolytics' oncolytic virus-based therapy granted US FDA Orphan Drug designation
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service